450O Initial Monotherapy Results of a Phase I First-in-human Study of ULK1/2 Inhibitor DCC-3116 Alone and in Combination with MAPK Pathway InhibitionA. W. Tolcher,D. S. Hong,A. Vandross,R. Amaravadi, C. Psoinos, D. Brennan,M. L. Sherman,R. Ruiz-Soto,L. Viswanathan,K. Sprott,F. J. Reu,C. D. WeekesAnnals of Oncology（2022）引用 0|浏览24AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
